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Abstract Current tools for cardiovascular disease (CVD)
risk assessment in asymptomatic individuals are imperfect.
Preventive measures aimed only at individuals deemed high
risk by current algorithms neglect large numbers of low-risk
and intermediate-risk individuals who are destined to
develop CVD and who would benefit from early and
aggressive treatment. Natriuretic peptides have the potential
both to identify individuals at risk for future cardiovascular
events and to help detect subclinical CVD. Choosing the
appropriate subpopulation to target for natriuretic peptide
testing will help maximize the performance and the cost
effectiveness. The combined use of multiple risk markers,
including biomarkers, genetic testing, and imaging or other
noninvasive measures of risk, offers promise for further
refining risk assessment algorithms. Recent studies have
highlighted the utility of natriuretic peptides for preopera-
tive risk stratification; however, cost effectiveness and
outcomes studies are needed to affirm this and other uses
of natriuretic peptides for cardiovascular risk assessment in
asymptomatic individuals.
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Introduction
Successful prevention of cardiovascular disease (CVD) is
predicated on accurate risk assessment to identify individ-
uals most likely to benefit from specific interventions.
Consensus statements regarding prevention of CVD there-
fore direct significant focus upon their risk assessment
recommendations. Whereas older guidelines often focused
exclusively on traditional cardiovascular risk factors for
assessment of risk [1], recent consensus statements have
begun to note the shortcomings of relying solely on this
approach while heralding the potential of novel assessment
methods, including the use of subclinical measures of
disease and cardiovascular biomarkers [2].
Traditional cardiovascular risk factors, although certainly
important to incorporate into any risk assessment, are not
sufficient for assessing CVD risk. According to the Third
National Health and Nutrition Examination Survey
(NHANES-3), over 99% of men and women between the
ages of 35 and 74 years have at least one suboptimal risk
factor [3]. It is not surprising, then, that major coronary
heart disease (CHD) risk factors are highly prevalent even
among individuals who never develop heart disease [4]. At
the same time, traditional risk factors do not fully explain
cardiovascular risk [5, 6]. The poor specificity and
suboptimal predictive value of traditional risk factors, in a
setting where early detection of subclinical CVD could lead
to prevention of future problems with early treatment,
points to the need for better ways to predict cardiovascular
risk in asymptomatic individuals.
Cardiovascular biomarkers are emerging as valuable
tools in assisting with disease prognosis and risk stratifica-
tion for a variety of cardiovascular conditions. The
natriuretic peptides (NPs), including B-type natriuretic
peptide (BNP) and the N-terminal fragment of pro-BNP
(NT-proBNP), are released in the setting of myocardial
strain and are well established for aiding in the diagnosis,
prognosis, and monitoring of heart failure patients [7].
Emerging data suggest that NPs also have predictive value
in a variety of other settings, including apparently healthy
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community dwellers, in whom elevated levels are associat-
ed with increased risk of cardiovascular morbidity and
mortality and may reflect subclinical myocardial or valvular
disease [8, 9]. They are therefore good candidate markers
for evaluating asymptomatic individuals who may have
subclinical cardiovascular abnormalities or who may be at
risk for future cardiovascular events.
Shortcomings of Currently Used Tools
for Cardiovascular Disease Risk Assessment
Tools commonly used for CVD risk assessment are often
based on measurement of traditional risk factors, such as
blood pressure, cholesterol, and smoking status, and have
several limitations. The National Cholesterol Education
Program Adult Treatment Panel III risk assessment [10] and
the Framingham risk score [11] are two such tools that,
although well validated and useful for thinking about risk on a
population level, have a number of shortcomings when used
in the individual patient. By principally targeting individuals
deemed “high risk” by current assessment tools, we are still
missing the majority of people who will ultimately develop
CVD. To paraphrase a classic paradox, the large number of
people at low risk for CVD may give rise to more cases of
CVD than the small number who are at a high risk [12].
The paradigm of treating high-risk patients by lowering
their blood pressure and cholesterol to a prespecified target
level also neglects the fact that regardless of the starting value,
for any given absolute change in blood pressure or cholesterol
there is a constant relative change in cardiovascular risk
(Fig. 1) [13]. Thus, if we could more accurately identify
individuals at risk for CVD, aggressive treatment may help
prevent CVD even among individuals without marked
hypertension or dyslipidemia.
Other shortcomings of global risk assessment tools
include an underestimation of life-time risk, poorer estima-
tion of risk in ethnic minority populations, a focus on only
CHD events rather than the full spectrum of CVD events
worthy of prevention (which includes cerebrovascular
disease and peripheral vascular disease in addition to
CHD), and the documentation of subclinical disease among
many individuals (especially women) whose score classi-
fies them as being at low risk [2, 14].
Natriuretic Peptides for Risk Assessment
and Cardiovascular Screening
BNP Versus NT-proBNP
Although they tend to be well correlated, absolute levels of
the two NPs are not interchangeable, and it is helpful for
clinicians to understand the differences and nuances
between them. On the occasions where there is a discrep-
ancy in relative levels, personal experience and some data
have suggested that it tends to be the NT-proBNP that is the
proportionally higher of the two values, which may in part
reflect its longer half-life compared with BNP. In this small
proportion of cases where the two tests disagree, NT-
proBNP may perform better [15•].
Performance characteristics for BNP and NT-proBNP are
similar in many clinical scenarios, including risk assessment
and cardiovascular screening [16]. However, some studies
have suggested that NT-proBNP may perform marginally
better than BNP in predicting mortality in the community
[17, 18] and in screening asymptomatic individuals for
structural heart disease [15•, 19].
Natriuretic Peptides and Cardiovascular Disease Risk
Assessment
Enthusiasm for using NPs for assessment of CVD risk has
grown out of a number of community-based studies
showing that levels are predictive of future cardiovascular
morbidity and mortality, even among apparently healthy
individuals. For example, the Framingham Offspring Study
prospectively measured BNP levels in 3,346 asymptomatic
middle-aged participants and found them to be indepen-
dently predictive of death, heart failure, stroke or transient
ischemic attack, and atrial fibrillation, even after adjusting
for traditional risk factors [8]. Participants with BNP levels
Fig. 1 Relative risk of coronary heart disease (CHD) by cholesterol
concentration. (Adapted from Jackson et al. [13]; with permission.)
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above the 80th percentile (∼20 pg/mL) had a 62% increased
risk of death and a 76% increased risk of a first major
cardiovascular event. With each increase in standard
deviation in log BNP levels, there was a 27% increased
risk of death, a 77% increased risk of heart failure, a 66%
increased risk of atrial fibrillation, and a 53% increased risk
of stroke or transient ischemic attack. NT-proBNP fared
similarly in a Danish community-based study where levels
were predictive of mortality and first major cardiovascular
event (nonfatal myocardial infarction, fatal CHD, unstable
angina, heart failure, stroke, and transient ischemic attack)
and provided prognostic information beyond traditional risk
factors [20]. These findings have since been replicated in
numerous studies [9, 21–28]. Thus, NPs may serve as an
early warning sign, alerting asymptomatic individuals to
their increased risk of CVD.
A Combined Approach: Screening for Subclinical CVD
Plus Risk Assessment
One distinct advantage of using NPs for cardiovascular risk
assessment is that in addition to helping predict future
cardiovascular events, NPs may also help to screen for
prevalent subclinical cardiovascular disease. Important
considerations for a successful population-based screening
test include a high prevalence of the disease being screened,
a safe and cost-effective test, and a proven effective
treatment for the detected disease (Table 1) [29]. NPs are
attractive candidates to screen for CVD in the general
population for several reasons [30]. First, the cardiovascular
diseases that are detectable by elevated NP levels, including
left ventricular dysfunction, cardiac dysrhythmias, and
valvular disease, are common and cause significant mor-
bidity and mortality. Second, NP levels are often elevated
early on in the disease process of patients who go on to
develop left ventricular dysfunction as well as other
cardiovascular conditions, allowing for timely detection of
disease prior to symptom onset [31•, 32]. Third, early
treatment of latent disease may improve outcomes; for
example, early use of angiotensin-converting enzyme
inhibitors may prevent the development of heart failure in
patients with asymptomatic left ventricular dysfunction
[33], and the development of arterial hypertension could
be prevented with earlier initiation of angiotensin-receptor
blocker therapy [34]. Finally, several studies have shown
that, in the proper setting of targeted higher-risk popula-
tions, NPs may prove cost effective for screening for CVD
[35–37].
Screening tests have better value in populations with a
higher prevalence of disease. The value of NPs in assessing
cardiovascular risk is bolstered by the fact that they can
both detect and predict a variety of clinical disorders. When
NPs are used to screen only for left ventricular dysfunction,
results have been mixed [15, 38–43]. However, when used
to screen for the presence of a variety of cardiovascular
diseases [35, 44], or to assess risk across the broader
spectrum of CVD, NPs have consistently emerged as strong
predictors. An approach that capitalizes on both the
screening and the risk assessment capabilities of NPs may
have the greatest chance of improving care.
Targeting Specific Subpopulations
The ultimate success of NPs as a tool for risk assessment
likely hinges upon identifying and targeting appropriate
subpopulations. Risk assessment tools rarely are indicated
for every individual regardless of age, gender, or other risk
factors, even when the aim is primary prevention. Rather,
by targeting groups with high-risk features, the accuracy
and cost effectiveness of risk assessment can be improved.
In the case of screening asymptomatic individuals with
NPs, a strategy targeting moderate-risk or higher-risk
groups has a much higher likelihood of success than does
a shotgun approach of evaluating every single individual.
Individuals currently considered to be at moderate risk
for CVD may stand to benefit the most from assessment
with NPs. Examples include individuals with borderline or
only single abnormalities of traditional risk factors (such as
those with a family history of CVD but no other risk
factors, those with isolated hypertension, or the elderly),
those with a Framingham risk score of 10% to 20%, and
those with atypical symptoms of CVD. We have recently
shown in a cohort of 829 outpatients referred for an
echocardiogram that individuals who are at risk for
heart failure but who are asymptomatic (American Heart
Association/American College of Cardiology Stage A or B)
with elevated BNP levels (≥100 pg/mL) are actually at
equal or higher risk for future cardiovascular events than
Table 1 World Health Organization criteria for screening
The condition sought should be an important health problem for the
individual and community
There should be an accepted treatment or useful intervention for
patients with the disease
Facilities for diagnosis and treatment should be available
There should be a recognizable latent or early symptomatic stage
There should be a suitable and acceptable screening test
The natural history of the disease, including development from latent
to declared disease, should be adequately understood
There should be an agreed policy on whom to treat as patients
The cost (including diagnosis and treatment of patients diagnosed)
should be economically balanced in relation to possible expenditure
on medical care as a whole
Case-finding should be a continuing process and not a “once and for
all” project
(Adapted from Wilson [29].)
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are individuals with a history of heart failure whose BNP is
less than 100 pg/mL (Fig. 2) [45]. Thus, NPs may be useful
to identify asymptomatic individuals at high risk for future
cardiovascular events. In moderate-risk individuals who
may be undecided about starting medications for primary
prevention, a markedly abnormal NP level may tilt the
balance in favor of treatment.
Individuals at highest risk for CVD in whom aggressive
preventive treatment is already recommended, including
those with chronic kidney disease, diabetes, or peripheral
vascular disease, may actually be in less-attractive sub-
groups to measure NP levels for risk assessment, although a
low NP level in these individuals could encourage a more
simplified approach to future testing with a high negative
predictive value [42]. Conversely, assessment of NP levels
in very low-risk subgroups such as young, healthy
individuals without any traditional risk factors is unlikely
to prove economically attractive. However, if relatively
inexpensive yet highly accurate screening panels become
available that include NPs as one part of a multi-marker
approach, even this paradigm could change.
Recent Advances
Multi-Marker and Multi-Modality Approach
Interest in a multi-marker (or multi-modality) approach to
risk assessment is growing, as reflected by the number of
recent studies evaluating such strategies. The rationale for
combining multiple risk markers is compelling, as such an
approach can extract information from a variety of distinct
pathophysiologic pathways, potentially broadening the
scope and sensitivity of risk prediction [46]. We have only
begun to scratch the surface on exploring combinations of
biomarkers, genetic testing, and imaging or other noninva-
sive measures of risk. Along these lines, Shaw et al. [47•]
recently showed that BNP and coronary artery calcium
scores were each independent predictors of cardiovascular
events in 2,458 asymptomatic adults recruited from a pool
of general medicine outpatients (Fig. 3). In this study, BNP
was the second strongest predictor of events (after coronary
artery calcium score) over a median of 4 years of follow-up,
even after accounting for the Framingham risk score.
Combining distinct risk markers for risk prediction requires
more study, but because of the complementary information
provided, this approach is promising.
The importance of a multi-pronged approach is high-
lighted by several studies suggesting that NPs may be less
robust markers in asymptomatic individuals for predicting
CHD risk specifically, compared with its utility for
predicting CVD risk. This was first suggested by the
Framingham Offspring data, where NP levels were not
significantly associated with the risk of CHD events,
despite being associated with CVD in general (adjusted
hazard ratios [95% CI per 1 standard deviation increase in
BNP] of 1.10 [0.89–1.37; P=0.37] for CHD events versus
1.28 [1.03–1.59; P=0.03] for first major CVD event) [8]. In
the past year, similar findings were reported by Tsuchida
and Tanabe [28], who showed that despite an increased risk
of cardiovascular events, cardiovascular mortality, all-cause
mortality, heart failure, stroke, and atrial fibrillation among
3,123 consecutive outpatients with elevated BNP, there was
no increased risk of CHD (hazard ratios for BNP level
≥100 pg/mL compared with BNP <100 pg/mL were 4.6
[3.5–6.1; P<0.0001] for CVD events versus 0.6 [0.2–1.7;
P=0.34] for CHD events). However, there is significant
heterogeneity in studies that report the magnitude of the
association between NP levels and CHD risk. Meta-
analyses and several other recent studies have found that
NP levels are in fact predictive of coronary events as well
as CVD events in asymptomatic individuals, albeit often
with slightly lower risk estimates [20, 21, 23, 26, 48, 49].
Melander et al. [22] demonstrated that of six novel and
conventional biomarkers studied in 5,067 community-based
Swedish participants without CVD, only NT-proBNP was
predictive of both CVD and CHD events.
In studies evaluating multi-marker approaches to CVD
risk assessment, NPs consistently emerge as important
contributors [22, 24, 50]. However, in several of these
studies the combination of multiple biomarkers only
marginally increased the C-statistic for risk prediction [22,
50]. Some researchers have therefore concluded that the use
of multiple biomarkers, as studied to date, has added only
Fig. 2 Unadjusted event-free survival over 1 year in four groups based
on American College of Cardiology/American Heart Association heart
failure stage and B-type natriuretic peptide (BNP) level among 829
outpatients referred for an echocardiogram. High BNP is ≥100 pg/mL
and low BNP is <100 pg/mL. The P value is from the log-rank test for
comparison across groups. (Adapted from Daniels et al. [45]; with
permission.)
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moderately to overall risk prediction based on traditional
cardiovascular risk factors [51]. On the other hand, relying
solely on the C-statistic may have limited utility for
assessing future risk in a currently healthy population
[52]. The final words are far from written on the optimal
combination of risk markers and on the specifics regarding
the best way to utilize a multi-marker approach to assess
asymptomatic individuals.
Preoperative Risk Assessment
Several recent publications have evaluated NPs for assess-
ing preoperative risk. In a meta-analysis of nine studies
including a total of 3,281 patients undergoing noncardiac
surgery, Karthikeyan et al. [53] examined the association
between elevated preoperative levels of NPs with major
adverse cardiac events within 30 days. All nine studies
showed an association between elevated preoperative NP
levels and adverse cardiac outcomes, with a pooled odds
ratio of 19.3 (95% CI, 8.5–43.7) after adjusting for other
risk factors. Ryding et al. [54] had strikingly similar
findings in their meta-analysis, which included 15 publica-
tions comprising 4,856 patients undergoing noncardiac
surgery (odds ratio of 19.8; 95% CI, 13.2–29.7), whereas
Rodseth et al. [55] showed the same in a meta-analysis of
1,127 vascular surgery patients (odds ratio of 17.4; 95% CI,
3.3–91.2). These and other studies have also shown the
converse (ie, patients with normal preoperative NP levels
had a very low risk of adverse cardiac events) [55–57]. This
has raised speculation that an NP-guided algorithm for
preoperative risk assessment may be cost effective [58],
whereby individuals with normal NP levels could poten-
tially proceed directly to surgery without further expensive
invasive and noninvasive testing, whereas those with
elevated levels may benefit from further risk stratification
and optimization of medications plus more intensive intra-
operative and perioperative monitoring.
Screening for Left Ventricular Dysfunction
The purpose of screening tests is to identify cardiac
functional and structural abnormalities at an early stage.
Over the past decade, NP levels have been evaluated as a
tool to screen asymptomatic individuals for left ventricular
dysfunction in a variety of settings [40, 59, 60]. Recent
studies shed further light on this area. In 2009, Betti et al.
[42] showed in 1,012 asymptomatic individuals at high risk
for heart failure because of diabetes and/or hypertension
that the cut-point of NT-proBNP less than 125 pg/mL had
an excellent negative predictive value of nearly 100% for
ruling out asymptomatic left ventricular dysfunction. If this
finding results in fewer echocardiograms for high-risk
patients such as these, NP testing could prove cost effective
in this situation.
Despite the high negative-predictive value among high-
risk individuals, the utility of NPs as a screening tool for
left ventricular dysfunction in the community has often
proved suboptimal. de Lemos et al. [15•] systematically
evaluated false-positive and false-negative screening eval-
uations in 2,429 population-based participants from the
Dallas Heart Study. Characteristics associated with false-
negative NP values included younger age, lower left
ventricular mass, higher left ventricular ejection fraction,
and a trend toward better renal function; characteristics
associated with false-positive NP values included older age,
poorer renal function, higher prevalence of coronary artery
calcification, and greater left ventricular mass.
Although NPs did not accurately discriminate individu-
als with left ventricular systolic dysfunction overall,
performance among high-risk men (age ≥50 years or with
hypertension) was comparable to other commonly used
screening tests such as prostate-specific antigen screening
for prostate cancer, Papanicolaou smears for cervical
cancer, and mammography for breast cancer (area under
the curve of 0.70 and 0.85, respectively) [15•, 61–63].
Furthermore, as described by the authors, previous
population-based studies that have also shown suboptimal
performance of NPs for screening for left ventricular
dysfunction have subsequently shown that high levels are
nonetheless predictive of worse cardiovascular outcomes.
This suggests that NP levels reflect more than the structural
and functional abnormalities that are seen on echocardio-
gram. Further support comes from a recent study by
Mogelvang et al. [31•] in which 1,012 community-based
participants underwent echocardiography. They found that
preclinical systolic and diastolic dysfunction, as assessed by
tissue Doppler imaging, was associated with elevated
Fig. 3 Cumulative cardiovascular event-free survival in patients with
combined B-type natriuretic peptide (BNP) and coronary artery
calcium (CAC) measurements. HR hazard ratio. (Adapted from Shaw
et al. [47•]; with permission.)
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plasma proBNP levels, even when conventional echocardi-
ography was normal. NPs seem to represent a synthesized
measure of an individual’s cardiovascular risk, which, in
addition to reflecting overt cardiac abnormalities, also
reflects physiologic perturbations of minor structural and
functional cardiac abnormalities as well as other factors,
such as renal dysfunction [15•].
Controversies and Future Directions
One difficulty inherent to any approach that uses
biomarkers to stratify risk is how to choose the optimal
cut-point for action. Choosing a cut-point makes a binary
variable out of a continuous one, and although this greatly
simplifies clinical use, a significant amount of information
is lost in the translation. Furthermore, the tension between
sensitivity and specificity is a transcendent one in cut-
point selection (as attested to by the frequently changing
guidelines for low-density lipoprotein cholesterol targets,
systolic blood pressure goals, and the fasting glucose level
needed for a diagnosis of diabetes.) Choosing an ideal NP
cut-point is even more complicated due to intra-individual
variability as well as the variability in baseline levels
based on the population being screened. This makes it
unlikely that any single cut-point will be sufficiently
acceptable across all populations.
Future studies evaluating NPs (or any new marker or
multi-marker panel) for risk assessment will benefit from
incorporating several newer statistical methods that have been
developed and recommended for gauging the information
provided by a new risk marker [64, 65••]. In addition to
conventional analyses such as proportional hazards models,
newer performance criteria include measures of discrimina-
tion, calibration, validation, and reclassification. However,
statistical methods alone cannot measure the full clinical
value of the information provided by a new risk marker. The
goal of improving risk assessment is to improve how we
respond to various risk categories; therefore, the effect of the
risk marker on clinical decisions and clinical outcomes is
ultimately the data in which we should be most interested.
Conclusions
There are insufficient data at the present time to recommend
a strategy of NP-guided risk assessment for asymptomatic
individuals in the population at large. However, accumu-
lating evidence suggests that an NP-guided approach may
make a positive impact in select subpopulations, including
those at intermediate or higher risk for CVD and those
undergoing preoperative evaluation. While we await cost-
effectiveness and outcome studies to confirm these uses of
NPs, investigations will continue to search for the best
recipe of other subgroups that may benefit, plus new
markers and combinations of risk markers that can make
assessing cardiovascular risk ever more accurate.
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